Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.9
5.1
Journals
Cells
Special Issues
Cell Biology for Boron Neutron Capture Therapy (BNCT)
share announcement

Cell Biology for Boron Neutron Capture Therapy (BNCT)

A special issue of Cells (ISSN 2073-4409).

Deadline for manuscript submissions: 31 December 2024 | Viewed by 3952

Special Issue Editors

Prof. Dr. Wolfgang Sauerwein

E-Mail Website
Guest Editor
1. Radiation Oncology, University Hospital Essen, University Duisburg, Strahlenklinik, Hufeland Street 55, 45122 Essen, Germany
2. Neutron Therapy Research Center, Okayama University, Okayama 700-8530, Japan
3. German Society for Boron Neutron Capture Therapy, 45122 Essen, Germany
Interests: radiation oncology; hadron therapy; boron neutron capture therapy (BNCT); neutrons; high-LET radiation; radiation biology; eye tumors; ophthalmic oncology
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Mitsuko Masutani

E-Mail Website
Guest Editor
1. Department of Molecular and Genomic Biomedicine, Center for Bioinformatics and Molecular Medicine, Nagasaki University Graduate School of Biomedical Sciences, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan
2. Visiting Scientist, Central Radioisotope Division, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
Interests: radiation oncology; biology in anti-cancer treatment; polyADP-ribosylation; anti-tumor therapeutic; mouse; boron neutron capture therapy
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Lucie Sancey

E-Mail Website1 Website2
Guest Editor
Institute for Advanced Biosciences INSERM U1209, CNRS UMR5309 UGA, Allée des Alpes-Site Santé, 38700 La Tronche, France
Interests: cancer biology; imaging; BNCT; elemental imaging; activable X-ray nanodrugs; theranostic compounds
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. John Hopewell

E-Mail Website
Guest Editor
Radiobiological Research, University of Oxford, Oxford OX1 2JD, UK
Interests: clinically oriented radiation biology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear colleagues,

The emergence of epithermal neutron sources in hospitals has made boron neutron capture therapy (BNCT) a focus of innovative developments in radiation oncology.

Given the rapid progress in clinical and preclinical research on BNCT, we invite contributions for this Special Issue of Cells in the form of original research articles and reviews on all cellular aspects related to BNCT.

Relevant topics include, but are not limited to, the following:

  • Radiation biology for BNCT;
  • Cell-based studies;
  • Drug development for BNCT;
  • Impact of BNCT on the proteomic profile and omics approaches;
  • Boron imaging;
  • Mechanisms of action of BNCT;
  • Immunological aspects, including abscopal effect of BNCT;
  • Biomarkers for therapeutic optimization.

Prof. Dr. Wolfgang Sauerwein
Prof. Dr. Mitsuko Masutani
Prof. Dr. Lucie Sancey
Prof. Dr. John Hopewell
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • boron neutron capture therapy (BNCT)
  • radiation biology
  • radiation oncology
  • drug development
  • imaging
  • targeted therapies
  • boron chemistry

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Related Special Issues

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

14 pages, 6553 KiB  
Article
Therapeutic Effect of Boron Neutron Capture Therapy on Boronophenylalanine Administration via Cerebrospinal Fluid Circulation in Glioma Rat Models
by Sachie Kusaka, Nikolaos Voulgaris, Kazuki Onishi, Junpei Ueda, Shigeyoshi Saito, Shingo Tamaki, Isao Murata, Takushi Takata and Minoru Suzuki
Cells 2024, 13(19), 1610; https://doi.org/10.3390/cells13191610 - 25 Sep 2024
Viewed by 947
Abstract
In recent years, various drug delivery systems circumventing the blood–brain barrier have emerged for treating brain tumors. This study aimed to improve the efficacy of brain tumor treatment in boron neutron capture therapy (BNCT) using cerebrospinal fluid (CSF) circulation to deliver boronophenylalanine (BPA) [...] Read more.
In recent years, various drug delivery systems circumventing the blood–brain barrier have emerged for treating brain tumors. This study aimed to improve the efficacy of brain tumor treatment in boron neutron capture therapy (BNCT) using cerebrospinal fluid (CSF) circulation to deliver boronophenylalanine (BPA) to targeted tumors. Previous experiments have demonstrated that boron accumulation in the brain cells of normal rats remains comparable to that after intravenous (IV) administration, despite BPA being administered via CSF at significantly lower doses (approximately 1/90 of IV doses). Based on these findings, BNCT was conducted on glioma model rats at the Kyoto University Research Reactor Institute (KUR), with BPA administered via CSF. This method involved implanting C6 cells into the brains of 8-week-old Wistar rats, followed by administering BPA and neutron irradiation after a 10-day period. In this study, the rats were divided into four groups: one receiving CSF administration, another receiving IV administration, and two control groups without BPA administration, with one subjected to neutron irradiation and the other not. In the CSF administration group, BPA was infused from the cisterna magna at 8 mg/kg/h for 2 h, while in the IV administration group, BPA was intravenously administered at 350 mg/kg via the tail vein over 1.5 h. Thermal neutron irradiation (5 MW) for 20 min, with an average fluence of 3.8 × 1012/cm2, was conducted at KUR’s heavy water neutron irradiation facility. Subsequently, all of the rats were monitored under identical conditions for 7 days, with pre- and post-irradiation tumor size assessed through MRI and pathological examination. The results indicate a remarkable therapeutic efficacy in both BPA-administered groups (CSF and IV). Notably, the rats treated with CSF administration exhibited diminished BPA accumulation in normal tissue compared to those treated with IV administration, alongside maintaining excellent overall health. Thus, CSF-based BPA administration holds promise as a novel drug delivery mechanism in BNCT. Full article
(This article belongs to the Special Issue Cell Biology for Boron Neutron Capture Therapy (BNCT))
►▼ Show Figures

Figure 1

Other

Jump to: Research

15 pages, 515 KiB  
Protocol
Early Stage In Vitro Bioprofiling of Potential Low-Molecular-Weight Organoboron Compounds for Boron Neutron Capture Therapy (BNCT)—Proposal for a Guide
by Zbigniew J. Leśnikowski, Filip Ekholm, Narayan S. Hosmane, Martin Kellert, Eiji Matsuura, Hiroyuki Nakamura, Agnieszka B. Olejniczak, Luigi Panza, Louis M. Rendina and Wolfgang A. G. Sauerwein
Cells 2024, 13(10), 798; https://doi.org/10.3390/cells13100798 - 8 May 2024
Cited by 1 | Viewed by 1940
Abstract
Given the renewed interest in boron neutron capture therapy (BNCT) and the intensified search for improved boron carriers, as well as the difficulties of coherently comparing the carriers described so far, it seems necessary to define a basic set of assays and standardized [...] Read more.
Given the renewed interest in boron neutron capture therapy (BNCT) and the intensified search for improved boron carriers, as well as the difficulties of coherently comparing the carriers described so far, it seems necessary to define a basic set of assays and standardized methods to be used in the early stages of boron carrier development in vitro. The selection of assays and corresponding methods is based on the practical experience of the authors and is certainly not exhaustive, but open to discussion. The proposed tests/characteristics: Solubility, lipophilicity, stability, cytotoxicity, and cellular uptake apply to both low molecular weight (up to 500 Da) and high molecular weight (5000 Da and more) boron carriers. However, the specific methods have been selected primarily for low molecular weight boron carriers; in the case of high molecular weight compounds, some of the methods may need to be adapted. Full article
(This article belongs to the Special Issue Cell Biology for Boron Neutron Capture Therapy (BNCT))
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop